FMP
Agile Therapeutics, Inc.
AGRX
NASDAQ
Inactive Equity
Agile Therapeutics, Inc., a women's healthcare company, researches, develops, and commercializes prescription contraceptive products for women in the United States. Its lead product is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Agile Therapeutics, Inc. was incorporated in 1997 and is headquartered in Princeton, New Jersey.
1.51 USD
0.05 (3.31%)
Operating Data
Year
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
Revenue
20.34M
15.6M
23.19M
79.86M
82.11M
108.42M
143.17M
189.06M
249.65M
329.66M
Revenue %
-
-23.3
48.68
244.31
2.81
32.05
32.05
32.05
32.05
Ebitda
-53.61M
53.29M
-35.12M
1.03M
-8.56M
-23.66M
-31.25M
-41.26M
-54.49M
-71.95M
Ebitda %
-263.61
341.63
-151.41
1.3
-10.43
-21.83
-21.83
-21.83
-21.83
Ebit
-54.24M
52.64M
-42.62M
-20.55M
-29.85M
-35.15M
-46.41M
-61.29M
-80.93M
-106.86M
Ebit %
-266.67
337.44
-183.74
-25.73
-36.35
-32.42
-32.42
-32.42
-32.42
Depreciation
622k
653k
7.5M
21.59M
21.28M
20.07M
26.5M
34.99M
46.2M
61.01M
Depreciation %
3.06
4.19
32.34
27.03
25.92
18.51
18.51
18.51
18.51
EBIT (Operating profit)(Operating income)(Operating earning) = GROSS MARGIN (REVENUE - COGS) - OPERATING EXPENSES (R&D, RENT) EBIT = (1*) (2*) -> operating process (leverage -> interest -> EBT -> tax -> net Income) EBITDA = GROSS MARGIN (REVENUE - COGS) - OPERATING EXPENSES (R&D, RENT) + Depreciation + amortization EBITA = (1*) (2*) (3*) (4*) company's CURRENT operating profitability (i.e., how much profit it makes with its present assets and its operations on the products it produces and sells, as well as providing a proxy for cash flow) -> performance of a company (1*) discounting the effects of interest payments from different forms of financing (by ignoring interest payments), (2*) political jurisdictions (by ignoring tax), collections of assets (by ignoring depreciation of assets), and different takeover histories (by ignoring amortization often stemming from goodwill) (3*) collections of assets (by ignoring depreciation of assets) (4*) different takeover histories (by ignoring amortization often stemming from goodwill)
